Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | FABP3 | P05413 | 5/20 | 0.42 |
| ▸ | FABP4 | P15090 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116255 | 0.89 | MAPT (0.46) | MAPTFABP3FABP4TSHRMEN1 | |
| SCHEMBL2932084 | 0.88 | MAPT (0.44) | MAPTMEN1KMT2AKDM4EPTGS2 | |
| SCHEMBL12856619 | 0.87 | MAPT (0.44) | MAPTFABP3FABP4TSHRMEN1 | |
| SCHEMBL12856631 | 0.87 | MAPT (0.44) | MAPTFABP3FABP4TSHRMEN1 | |
| SCHEMBL1116024 | 0.87 | MAPT (0.44) | MAPTFABP3FABP4TSHRMEN1 | |
| SCHEMBL12856603 | 0.85 | MAPT (0.46) | MAPTFABP3FABP4TSHRMEN1 | |
| SCHEMBL1115902 | 0.84 | FABP3 (0.45) | MAPTFABP3FABP4MEN1LMNA | |
| SCHEMBL1116205 | 0.84 | MAPT (0.42) | MAPTFABP3FABP4TSHRMEN1 | |
| SCHEMBL13176991 | 0.81 | MAPT (0.40) | MAPTFABP3FABP4TSHRPBRM1 | |
| SCHEMBL13989938 | 0.81 | MAPT (0.39) | MAPTFABP3FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910314-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-1910314-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| EP-1910314-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009774-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009774-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306064-A1 | Benzimidazole Derivatives | PPARG, PPARD, BRD4 | MAPT 2716/4885FABP3 793/4885FABP4 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.